0226 GMT - Forsyth Barr says pharmacy chain owner Ebos's 1H result was in line with its expectations, but by no means perfect. Community Pharmacy revenue beat consensus hopes. Contract Logistics growth was strong, while retaining FY 2026 guidance was another positive, Forsyth Barr says. It says negatives are the low quality of earnings, weak cash flow, and a miss on Community Pharmacy margins. "Overall, we think the result has done enough to provide the building blocks to rebuild investor confidence and meaningfully reduces the downside risks from here, but it will not be an overnight fix," analyst Matt Montgomerie says. Ebos is down 0.3% at NZ$24.02 today. Forsyth Barr retains an outperform call on the stock and trims its price target by 3.9% to NZ$35.80/share. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 25, 2026 21:26 ET (02:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.